Caribou Biosciences. has filed a patent for a monoclonal mouse or humanized ROR1 antibody, along with a chimeric antigen receptor (CAR) for ROR1. The claim specifies the amino acid sequences for the antibody components. GlobalData’s report on Caribou Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Caribou Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Caribou Biosciences, CRISPR genome editing was a key innovation area identified from patents. Caribou Biosciences's grant share as of January 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.

Monoclonal antibody for ror1 cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Caribou Biosciences Inc

The patent application (Publication Number: US20230383009A1) discloses a series of claims related to an anti-human ROR1 antibody and its antigen-binding fragments. The claims detail the specific amino acid sequences of the VH and VL regions of the antibody, as well as the inclusion of a humanized mouse amino acid sequence. Additionally, the claims describe the construction of a single-chain variable fragment (scFv) with specific VH and VL sequences, along with complementarity determining regions (CDRs) in both regions.

Furthermore, the patent application outlines the creation of a chimeric antigen receptor (CAR) using the scFv described earlier. The CAR includes components such as a transmembrane domain, co-stimulatory domains (CD28 or 4-1BB), an activation domain (CD3 zeta), as well as a signaling peptide and hinge domain. The CAR is designed for use in engineered immune cells, specifically CAR-T cells and CAR-NK (natural killer) cells, which are intended to be part of a composition along with an excipient. Overall, the patent application focuses on the development and utilization of these specific antibodies and CAR constructs for potential therapeutic applications in the field of immunotherapy.

To know more about GlobalData’s detailed insights on Caribou Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies